Search

Background: Generic drug prices have been capped at specified percentages of the interchangeable branded drug's price by the Canadian provincial public drug plans since 1993. The Pan-Canadian Pharmaceutical Alliance, formed as a coalition by the provinces/territories in Canada, implemented an alternative approach, a tiered-pricing framework (TPF) for new generic drugs on April 1, 2014, under which the percentage varies with the number of generic firms in each market. We evaluate the impact of the TPF on generic entry, ie, listing in public drug plans in Canada. Methods: Our study compared the pre-TPF period (01/01/2012-03/31/2014) with the TPF period (04/01/2014-06/30/2016). Prescription drugs from nine provincial public drug plans were grouped into a "market" if they had the same active ingredient and strength, route of administration, and dosage form. Each "market" was contestable by generics and met the eligibility criteria for TPF. At the "market" level, Cox proportional-hazards models with time-varying covariates were used to measure the impact of the TPF on the first generic listing in any provincial public drug plan in Canada relative to the first launch date worldwide. Results: A total of 189 markets in Canada were selected for the analyses. Generic drugs in small markets were more likely to be listed in Canada during the TPF period compared to the pre-TPF period (hazard ratio [HR], 95% CI: 3.81, 1.51-9.62). There was no significant difference in generic drug listings in large markets between the two policy periods. Conclusion: TPF speeds up generic entry in small markets and generates the benefits of generic competition while avoiding the pitfalls of the previously employed price-cap regulations. [ABSTRACT FROM AUTHOR]

The article discusses the impact of price negotiation through rebates to the drug expenditure of the patients. It highlights the development of publicly funded prescription insurance plans with a co-insurance payment structure for the patients. It also cites the confidentiality of pricing agreements between the government and pharmaceutical manufacturers.

The first generic entrant into Canadian pharmaceutical markets has a surprisingly durable impact on market share: consistent with past research, we show that first entrants have a boost of roughly 25% in their expected market share some six years after entry. There appears to be considerable inertia in pharmacies’ choice of which generic drug to stock. In this article, we empirically explore possible explanations for this puzzling phenomenon, including reputation, pharmacy “gratitude,” patient resistance to switching, and transactions costs. [ABSTRACT FROM PUBLISHER]

The article explores the problem in the pricing and procurement of orphan drugs using an old orphan drug, trientine, for the treatment of Wilson disease, as an example. Topics covered include the aim of the traditional laws for orphan drugs in Canada, the regulatory status of D-penicillamine and trientine as oral treatments for Wilson disease, in Canada, and the reason pharmaceutical firm Valeant Canada announced that the price of Syprine would match the U.S. price.

The article examines how parallel trade affects drug policies and prices in Canada and the U.S. U.S. consumers and Canadian pharmacies have taken advantage of the opportunity presented by price differences in patented pharmaceuticals. This brought the Canadian and U.S. systems for determining pharmaceutical pricing under increased scrutiny. It asserts that the price discrimination strategies of pharmaceutical manufacturers and exchange rate fluctuate have played an underappreciated role.

This paper examines the price effects of generic drugs that are produced by brand-name drug firms and that are labeled, priced, and marketed to compete against independent generics. The strategy of introducing such "pseudo-generics" - also known as "authorized generics" - has raised some antitrust concerns. One defense of this strategy has been that the additional competition created by pseudo-generics should lead to lower prices. This paper develops a simple model to show that pseudo-generics can be expected to have exactly the opposite effect. It then examines empirical evidence on this point from the Canadian pharmaceutical market, showing that there appears to be a positive relationship between drug prices and the share of generic sales made by the brand's own pseudo-generic. [ABSTRACT FROM AUTHOR]

Drug plans take different approaches to determining reimbursement prices for generic drugs. One common approach is to set the maximum reimbursement price as a percentage of the price of the interchangeable branded drug. In many countries this percentage depends on the number of generic entrants, a model we call "tiered pricing." This paper seeks to enhance understanding of how to set the tiers. We construct a simple model of tiered pricing and set parameters to match evidence on generic drug costs and the distribution of revenues. Using simulation methods, we then assess different tier structures in terms of total surplus and average drug cost. We find when tiers are bunched tightly together welfare outcomes are poor. Moreover, there are large welfare gains from increasing the number of tiers from one to two, and only small welfare gains from increasing the number of tiers beyond four. The choice of tiers has substantial welfare and cost implications. While it is possible to refine the simulation analysis based on specific market characteristics, an optimal tier structure, such as the one we propose in the paper, should have at least two tiers. [ABSTRACT FROM AUTHOR]